Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer

European Journal of Cancer

Volumn 38, Issue 3, 2002, Pages 349-358

  Borner, M M ^a   Schöffski, P ^a   De Wit, R ^a   Caponigro, F ^a   Comella, G ^a   Sulkes, A ^a   Greim, G ^a   Peters, G J ^b   Van der Born, K ^b   Wanders, J ^d   De Boer, R F ^d   Martin, C ^c   Fumoleau, P ^a  

^a EORTC DATA CENTER   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRISTOL MYERS SQUIBB   (United States)

^d New Drug Development Office   (Netherlands)

Author keywords

5 Fluorouracil; Leucovorin; Oral; Patient's preference; Pharmacokinetics; Randomised crossover trial; UFT

Indexed keywords

FLUOROURACIL; FOLINIC ACID; UFT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EXPOSURE; DRUG PREFERENCE; FEMALE; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; PLASMA CLEARANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; TEGAFUR; URACIL;

EID: 0036159485     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00371-9     Document Type: Article

References (22)

1. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
2. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial
3. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
4. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer
5. Clinical pharmacology of 5-fluorouracil
6. UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer
7. Oral fluoropoyrimidines
8. Multicenter phase III study of fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal Cancer
9. Randomized comparative study of UFT plus leucovorin (LV) versus parenteral fluorouracil plus LV in patients with metastatic colorectal cancer
10. Patient preferences for oral versus intravenous palliative chemotherapy
11. Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay
12. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma
13. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
14. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993
15. Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes
16. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule
17. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil
18. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion
19. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
20. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
21. Clinical pharmacokinetics of capecitabine
22. Improving the quality of reporting of randomised controlled trials: The CONSORT statement